Categories Earnings, Health Care

Lannett stock jumps more than 15% after topping Q4 earnings and revenue estimates

Generic drug manufacturer Lannett’s (NYSE: LCI) stock surged more than 15% after it reported Q4 earnings results. The company’s bottom line and top line results exceeded the market’s expectations. On a non-GAAP basis, Lannett earned 37 cents per share on revenue of $134 million for the final quarter of 2019.

Lannett stock, which ended down 3.21% at $6.03 today, jumped about 18% immediately in the extended trading session after the earnings announcement. Analysts had projected Lannett to post earnings of 21 cents per share on revenue of $121.88 million for the fourth quarter.

Lannett (LCI) stock jumps more than 15% after topping Q4 2019 earnings and revenue estimates

On a GAAP basis, net loss was $7.6 million or $0.20 per share in the recently ended quarter compared with a loss of $11.4 million or $0.30 per share in the fiscal 2018 fourth quarter.

“Financial results for our fiscal 2019 fourth quarter, the first full quarter of the fiscal year without sales of Levothyroxine, exceeded or were at the upper end of our expectations,” said CEO Tim Crew.

For fiscal 2020, the company expects revenue to be in the range of $525 million to $545 million. “Looking ahead, we expect to launch a number of new products that will continue to build our business in the near term and have begun adding products to our pipeline that have significant potential in the medium term and beyond,” added Crew.

Read: Amgen to take over Celgene’s OTEZLA for $13.4 billion; Bristol-Myers Squibb increases share buyback plan

In early July, FDA cleared the path for the continuing review of Lannett’s New Drug Application for cocaine hydrochloride topical solution. The Philadelphia, Pennsylvania-based company expects to receive the approval  in early 2020.

Earlier today, Lannett entered into a three-year advisory services agreement with its strategic alliance partner, Cediprof, a wholly-owned subsidiary of privately-held Neolpharma Group.

Read: Why Arbutus Biopharma stock dipped to 11-year low?

Under the new agreement, Lannett will advise on a wide array of matters broadly related to assisting Cediprof and its affiliated entities with their efforts to further develop and commercialize products for the U.S. generic market. Lannett will receive an advisory fee for its services.

Lannett shares have gained 22% so far this year and 18% in the past 52 weeks.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Infographic: Nvidia (NVDA) Q4 revenue up 61%; earnings beat

Nvidia Corporation (NASDAQ: NVDA) Wednesday said its fourth-quarter revenues and profit increased in double-digits amid elevated demand. The results also topped the Street view, driving the stock higher during the

Nutanix (NTNX) Earnings: 2Q21 Key Numbers

Nutanix (NASDAQ: NTNX) reported second quarter 2021 earnings results today. Total revenue remained flat at $346.4 million compared to the same period a year ago. GAAP net loss was $287.3

Macy’s (M) expects digital channels to generate approx. $10 billion in sales by 2023

Shares of Macy’s Inc. (NYSE: M) were down 2.7% in morning trade on Wednesday. The stock has gained 37% since the beginning of the year. A day ago, the retailer

Add Comment
Viewing Highlight